JFJohn Foerster

John Foerster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John Foerster has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Narrowband ultraviolet B phototherapy is associated with a reduction in topical corticosteroid and clinical improvement in atopic dermatitis: a historical inception cohort study

    by J. Y. Choi, M. Owusu‐Ayim, R. Dawe, S. Ibbotson, C. Fleming, J. Foerster

    Background Despite decades of use, the magnitude of efficacy of narrowband‐ultraviolet B phototherapy (NB‐UVB) for atopic dermatitis (AD) outwith industry‐sponsored trials remains unclear. Objective To evaluate the clinical efficacy of NB‐UVB in AD under real‐world conditions. Methods We conducted a historical inception cohort study using automated recording of drug dispensed to provide an objective treatment outcome in a large population catchment of 420,000 over 15 years. We analysed clinical treatment outcomes, recorded multicentre and prospectively over 15 years, as well as drug dispensed in a large AD treatment cohort (n = 844). Results 70% of AD patients received significantly less topical corticosteroids (TCS) during the 12‐month window after finishing NB‐UVB, compared to the 12‐month window before starting (median reduction from 37.5 to 19.7 gram/month). The number of patients dispensed with oral corticosteroid and antihistamines dropped significantly (from 20% to 10% and from 69% to 31%, respectively), while all AD‐unrelated drugs dispensed remained unchanged. Clinically, NB‐UVB treatment achieved a “clear” or “almost clear” status in 48.7% of patients and 20.4% of patients achieved “moderate clearance”. Treatment outcomes scores were validated by a strong correlation with reduction in AD‐specific drug treatment. Conclusion Our data confirm the significant efficacy of NB‐UVB for AD under conditions of routine care.


  • Open Access

    Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis

    by John Foerster, Aleksandra Molęda

    Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic disease has yet been licensed. The present review summarises recent scientific advances, identifying interleukin-13 as an excellent candidate to validate the concept of anti-cytokine vaccination. Based on numerous clinical studies, long-term elimination of IL-13 is not expected to trigger target-related serious adverse effects and is likely to be safer than combined targeting of IL-4/IL-13. Furthermore, recently published results from large-scale trials confirm that elimination of IL-13 is highly effective in atopic dermatitis, an exceedingly common condition, as well as eosinophilic esophagitis. The distinctly different mode of action of a polyclonal vaccine response is discussed in detail, suggesting that anti-IL-13 vaccination has the potential of outperforming monoclonal antibody-based approaches. Finally, recent data have identified a subset of follicular T helper cells dependent on IL-13 which selectively trigger massive IgE accumulation in response to anaphylactoid allergens. Thus, prophylactic IL-13 vaccination may have broad application in a number of allergic conditions.


  • Open Access

    MHC*IMP – Imputation of Alleles for Genes in the Major Histocompatibility Complex

    by David McG. Squire, Allan Motyer, Richard Ahn, Joanne Nititham, Zhi-Ming Huang, Jorge R. Oksenberg, John Foerster, Wilson Liao, Stephen Leslie

    We report the development of MHC*IMP, a method for imputing non-classical HLA and other genes in the human Major Histocompatibility Complex (MHC). We created a reference panel for 25 genes in the MHC using allele calls from Whole Genome Sequencing data, combined with SNP data for the same individuals. We used this to construct an allele imputation model, MHC*IMP, for each gene. Cross-validation showed that MHC*IMP performs very well, with allele prediction accuracy 93% or greater for all but two of the genes, and greater than 95% for all but four.


  • Open Access

    Phototherapy achieves significant cost savings by the delay of drug‐based treatment in psoriasis

    by John Foerster, Robert Dawe

    Background: Although used for decades in psoriasis, access to phototherapy is becoming increasingly restricted. Besides patient inconvenience, this is in large part to do with a perception of “high cost.” We previously reported a comprehensive analysis of direct and indirect phototherapy treatment cost. However, no robust data exist on the actual savings associated with providing phototherapy in the treatment pathway.Objectives: To quantify the cost savings achieved by phototherapy by delaying alternative treatments.Methods: Costs accruing through the UK‐wide established treatment pathway with and without phototherapy were analysed. Direct and indirectly incurred drug treatment costs were calculated using drug tariff, laboratory cost, estate rates and clinic review costs. To enhance reliability, ranges of cost scenarios were calculated by varying parameters such as drug dosing.Results: Medium annual cost savings per patient were £2200 [range: £1800‐£2900] for NB‐UVB, and £3700 [range: £2500‐£5300] if both NB‐UVB and PUVA courses were administered, respectively. As the provider treated 656 ± 76 patients per year during the 6‐year observational window, this amounted to savings of £Mio 2.4 [range: £Mio 1.6‐£Mio 3.4], even excluding additional non‐modelled drug‐associated costs (eg diagnostics, adverse event management). Since we only consider cost savings by delay of drug treatment for the duration of phototherapy, drug price reductions through biosimilar introduction only have a small effect. We provide spreadsheets allowing adaptation cost savings projections by varying input variables.Conclusions: Healthcare providers may achieve significant cost savings by implementing and/or widening access to phototherapy.


  • Quantitative analysis of topical treatments in atopic dermatitis: unexpectedly low use of emollients and strong correlation of topical corticosteroid use both with depression and concurrent asthma

    by J.Y. Choi, R. Dawe, S. Ibbotson, C. Fleming, A. Doney, J. Foerster

    Background Despite decades of use,the actual amounts of topical corticosteroids (TCS) and emollients used in moderate‐to‐severe atopic dermatitis (AD) under real‐world conditions are unknown. Thus, it remains unclear if inadequate use is widespread. OBJECTIVE: To quantify the use of TCS and emollients in moderate‐to‐severe AD. METHODS: Double‐blinded drug prescribing recorded prospectively at the point of drug dispensing within a catchment of approx. 450,000 over a 31‐year period in a population‐based cohort marked by failure of disease control in primary care (n = 844). For each patient, prescribing was recorded over 12‐month to minimize fluctuations. RESULTS: The resulting dataset was near‐complete, and essentially free of reporting‐ and recording bias. Atopic co‐morbidities matched expected frequencies. Median use of TCS was statistically significantly higher in juvenile (age < 16) compared to adult patients (49·2 vs. 38·1 gram / month), in males vs. females (46·8 vs. 29·7), and in patients receiving concurrent asthma treatment (40·4 vs. 26·7). TCS use was strongly associated with anti‐depressant treatment. Emollient use was unexpectedly low at median of 9·6 gram/day (range 1·4 ‐ 30·1). Results replicated in an independent validation cohort. Conclusions Deficient use of emollients may be a factor contributing to AD severity. TCS use does not exceed current guidelines. Accurate quantification of topical treatments provides a widely accessible strategy to measure real‐world impact of novel AD treatments.


  • Open Access

    Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine

    by John Foerster, Aleksandra Molęda

    Background: The development of therapeutic vaccines requires thorough knowledge of potential hazards associated with long-term inactivation of self-proteins. Among potential targets, interleukin 13 (IL-13) merits consideration, as monoclonal antibodies disrupting IL-13 signaling are proving to be exceedingly effective in common conditions such as atopic dermatitis. Objective: Given the mass publication of scientific data, an appraisal of safety aspects is challenging. Methods: We here provide a three-fold approach to survey clinically relevant information on off-target effects, both adverse and beneficial, that may potentially be encountered in patients undergoing long-term IL-13 inactivation. First, we review non-clinical data in vivo and in vitro. Second, we summarize safety data accumulating from patients dosed with anti-IL-13 drugs. Third, we exploit human mutation data as well as emerging large-scale genetic datasets (global exome data from 60,000 patients) to obtain information on any association of IL-13-inactivating genetic variants with disease states. In addition, we: (1) dissect the precise efficacy signals obtained with various drugs targeting IL-13 and/or IL-4, and (2) summarize unintended, but potentially beneficial effects of prolonged IL-13 inactivation on several functional systems. Results: Prolonged repression of IL-13 in several thousand patients so far has not uncovered any non-redundant functions of IL-13 in immune defense. Furthermore, missense mutations in the key genes IL-13, IL-13Rα1, IL-13Rα2, IL-4, IL-4Rα are common, while no case reports have been published on any immune deficiency or increased risk of neoplastic disease associated with such mutations, suggesting that these genes do not harbor non-redundant roles in adult outbred humans. In terms of efficacy, data from clinically used drugs strongly suggest that targeting IL-13 only, as opposed to IL-13 and IL-4, may be effective in eczema while being more selective. Importantly, several lines of evidence suggest that inhibition of IL-13 may in fact harbor potentially beneficial effects on non-targeted systems, including glucose metabolism, hepatic fibrosis, and atherosclerosis, suggesting that respective outcomes should be systematically captured in patients dosed with IL-13 interfering drugs. Collectively, available evidence suggests that IL-13 may fulfill safety requirements required for the target of a therapeutic vaccine.


  • 窄波 UVB 用于银屑病治疗的费用

    by K. Boswell, H. Cameron, J. West, C. Fleming, S. Ibbotson, R. Dawe, J. Foerster

  • Candidate long‐range regulatory sites acting on the IL17 pathway genes TRAF3IP2 and IL17RA are associated with psoriasis

    by Joanne Nititham, Calum Fergusson, Colin Palmer, Wilson Liao, John Foerster

    Background: Drug‐mediated disruption of IL17A, IL17F and IL17RA proteins is effective in psoriasis. However, disruption of the IL17 pathway by functional mutations has so far only been shown to affect risk in IL23R and TRAF3IP2. It is unclear whether this is due to rarity of disruptive mutations. Objective: (a) To delineate the prevalence of mutations in key IL17 pathway genes and (b) to identify candidate regulatory sites acting on IL23R, IL17A, IL17RA and TRAF3IP2 from a distance.Methods: Extraction of mutation frequencies from ExAc data, evolutionary sequence alignment; mapping of long‐range interacting (LRI) enhancers; and genetic association testing in a novel psoriasis cohort.Results: The prevalence of disruptive mutations in genes such as IL17RA is sufficient to have been detectable by existing data sets. Therefore, lack of their association with psoriasis indicates that genetic risk primarily resides in variants acting from a distance. We identify two LRI enhancer sites, regulating IL17RA and TRAF3IP2, respectively. The TRAF3IP2 regulator localizes to the TRAF3IP2 antisense promoter, suggesting feedback regulation. Both LRI sites are associated with psoriasis in a novel Scottish psoriasis cohort and the TRAF3IP2‐LRI at rs71562294 replicates in the WTCCC cohort.Conclusion: Genetic risk for psoriasis may be encoded at LRI sites regulating IL17 pathway genes from a distance.


  • Narrowband ultraviolet B treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments

    by K. Boswell, H. Cameron, J. West, C. Fleming, S. Ibbotson, R. Dawe, J. Foerster

    Background Narrowband ultraviolet B (NB‐UVB) treatment for psoriasis is considered expensive. However, existing data are based on estimates and do not consider indirect cost savings. Objectives To define the actual costs of NB‐UVB incurred by the service provider, as well as treatment‐associated cost savings. Methods We performed data linkage of (i) comprehensive treatment records and (ii) prescribing data for all NB‐UVB treatment episodes spanning 6 years in a population of 420 000. We minimized data fluctuation by compiling data from four independent treatment sites, and using drug prescriptions unrelated to psoriasis as a negative control. Results National Health Service Tayside spent an average of £257 per NB‐UVB treatment course (mean 257 ± 63, range 150–286, across four independent treatment sites), contrasting sharply with the estimate of £1882 used by the U.K. National Institute for Health and Care Excellence. The cost of topical treatments averaged £128 per patient in the 12 months prior to NB‐UVB, accounting for 42% of the overall drug costs incurred by these patients. This was reduced by 40% to £53 per patient over the 12‐month period following NB‐UVB treatment, while psoriasis‐unrelated drug prescription remained unchanged, suggesting disease‐specific effects of NB‐UVB. The data were not due to site‐specific factors, as confirmed by highly similar results observed between treatment sites operated by distinct staff. Finally, we detail all staff hours directly and indirectly involved in treatment, allowing direct translation of cost into other healthcare systems. Conclusions NB‐UVB is a low‐cost treatment; cost figures currently used in health technology appraisals are an overestimate based on the data presented here. Creating or extending access to NB‐UVB is likely to offer additional savings by delaying or avoiding costly third‐line treatments for many patients.


  • Open Access

    Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy

    by Andris Zeltins, Jonathan West, Franziska Zabel, Aadil El Turabi, Ina Balke, Stefanie Haas, Melanie Maudrich, Federico Storni, Paul Engeroff, Gary T. Jennings, et al.

    Monoclonal antibodies are widely used to treat non-infectious conditions but are costly. Vaccines could offer a cost-effective alternative but have been limited by sub-optimal T-cell stimulation and/or weak vaccine responses in recipients, for example, in elderly patients. We have previously shown that the repetitive structure of virus-like-particles (VLPs) can effectively bypass self-tolerance in therapeutic vaccines. Their efficacy could be increased even further by the incorporation of an epitope stimulating T cell help. However, the self-assembly and stability of VLPs from envelope monomer proteins is sensitive to geometry, rendering the incorporation of foreign epitopes difficult. We here show that it is possible to engineer VLPs derived from a non human-pathogenic plant virus to incorporate a powerful T-cell-stimulatory epitope derived from Tetanus toxoid. These VLPs (termed CMVTT) retain self-assembly as well as long-term stability. Since Th cell memory to Tetanus is near universal in humans, CMVTT-based vaccines can deliver robust antibody-responses even under limiting conditions. By way of proof of concept, we tested a range of such vaccines against chronic inflammatory conditions (model: psoriasis, antigen: interleukin-17), neurodegenerative (Alzheimer’s, β-amyloid), and allergic disease (cat allergy, Fel-d1), respectively. Vaccine responses were uniformly strong, selective, efficientin vivo, observed even in old mice, and employing low vaccine doses. In addition, randomly ascertained human blood cells were reactive to CMVTT-VLPs, confirming recognition of the incorporated Tetanus epitope. The CMVTT-VLP platform is adaptable to almost any antigen and its features and performance are ideally suited for the design of vaccines delivering enhanced responsiveness in aging populations.